Rasio rega marang prakiraan pendapatan Qilian International Corp (QLI)
The specifics of Qilian International (QLI) asset management in Asia necessitate increased compliance transparency, which is clearly demonstrated by the forward P/S ratio. Currently, the relevant mark stands at 4.20. Strict government licensing of Chinese raw materials stabilizes the situation by creating barriers for competitors, although the depreciation of production capacities limits margin growth and constrains the business's operational efficiency.
Qilian International Corp - rincian analitis lan metrik utama (QLI)
- rega saiki lan proyeksi nilai saham:
- rincian kapitalisasi pasar:
- indikator nilai buku ekuitas:
- rincian struktur utang lan likuiditas bisnis:
Utang marang Ekuitas Qilian International|QLI - Rasio utang jangka dawa marang modal|Rasio utang jangka cendhak marang ekuitas Qilian International|QLI - Kewajiban utang agregat|Utang-utang marang kapitalisasi buku Qilian International Corp|QLI - Gunggunge utang jangka dawa|Utang jangka cendhak perusahaan Qilian International|Indikator likuiditas cepet qlsyy.net
- rincian asil keuangan lan kelipatan valuasi:
QLI - Bathi sawise mbayar pajeg|Proyeksi bathi mangsa ngarep Qilian International|QLI - Kapitalisasi marang bathi|Rega marang bathi mangsa ngarep Qilian International Holding Group Limited|QLI - Koefisien bali modal nimbang wutah|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Qilian International Corp|QLI - Bathi operasional sadurunge amortisasi|Bathi resik saben saham (EPS TTM) Qilian International|QLI - Bathi resik saben saham (EPS TTM)|Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan qlsyy.net|QLI - Wutah bathi resik saben siji saham kanggo taun lumaku|Prakiraan wutah bathi kanggo taun ngarep Qilian International
- indikator volume dodolan lan pendapatan:
Ringkesan analisis perusahaan:Qilian International Holding QLI
The forward P/S reflects the market value of Qilian International (QLI) relative to its expected sales volume, allowing for an assessment of the premium or discount to projected revenue. By analyzing changes in the forward P/S, an investor determines the asset's margin of safety, which is critical for Qilian International (QLI) amid capacity modernization and expansion within the Asian organic fertilizer and traditional medicine segments.
Analisis perusahaan pesaing
Multiplikator Forward P/S HLN (Haleon)|Rasio kapitalisasi marang dodolan sing dikarepake Kenvue Inc (KVUE)|VRNA - Rasio rega marang prakiraan pendapatan|MENS: Rasio rega marang prakiraan pendapatan|LGND: Multiplikator Forward P/S|AMRX - Rasio kapitalisasi marang dodolan sing dikarepake|PRGO (Perrigo) - Multiplikator Forward P/S|Multiplikator Forward P/S Alvotech S.A.|Rasio rega marang prakiraan pendapatan Liquidia Technologies (LQDA)|Galapagos Corp - Kapitalisasi marang prakiraan pendapatan|ANI Pharmaceuticals - Multiplikator forward rega marang pendapatan|Rega forward marang dodolan MNKD|Amphastar Pharmaceuticals, Inc. - Multiplikator Forward P/S|Rasio kapitalisasi marang dodolan sing dikarepake Pacira Pharmaceuticals PCRX|ARS Pharma (SPRY) - Rasio rega marang prakiraan pendapatan|Kapitalisasi marang prakiraan pendapatan TBPH|Multiplikator forward rega marang pendapatan AQST|SCPH (scPharma) - Rasio rega marang pendapatan sing dikarepake|Multiplikator Forward P/S TECX|TNXP - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Rasio rega marang prakiraan pendapatan China SXT Pharmaceuticals, Inc. SXTC|Rega forward marang dodolan EPRX|BHST - Rasio rega marang prakiraan pendapatan|EXOZ (invizyne.com) - Kapitalisasi marang prakiraan pendapatan|ORMP: Multiplikator Forward P/S|Entera Bio (ENTX) - Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan HYFT|ABVC (ABVC BioPharma, Inc) - Rasio rega marang pendapatan sing dikarepake|Multiplikator Forward P/S CPIX|Rasio kapitalisasi marang dodolan sing dikarepake quantumbiopharma.com|Rasio rega marang prakiraan pendapatan FibroGen FGEN|Telomir Pharmaceuticals Inc (TELO) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|RANI - Rasio rega marang prakiraan pendapatan|SNYR (Synergy CHC Corp) - Kapitalisasi marang prakiraan pendapatan|RLYB: Multiplikator Forward P/S|Lexaria Bioscience Corp. (LEXX) - Multiplikator Forward P/S|Rasio rega marang prakiraan pendapatan Pulmatrix|Rasio rega marang prakiraan pendapatan PTHL|Rasio rega marang prakiraan pendapatan Aptorum Group Limited (APM)|Lyra Therapeutics Inc (LYRA) - Prakiraan rega marang pendapatan|Rasio rega marang prakiraan pendapatan Impact BioMedical Inc IBO|TNF Pharmaceuticals Inc. - Rasio rega marang prakiraan pendapatan|cbdMD Corp - Multiplikator Forward P/S|Rasio kapitalisasi marang dodolan sing dikarepake PainReform Ltd PRFX|altamiratherapeutics.com (CYTO) - Rasio rega marang prakiraan pendapatan|Rega mangsa ngarep marang pendapatan LIPO (Lipella Pharma)|OPTN (OptiNose, Inc.) - Multiplikator Forward P/S|PIRS: Rega forward marang dodolan|Multiplikator Forward P/S PROC|Multiplikator Forward P/S Petros Pharmaceuticals Inc (PTPI)|Rasio rega marang prakiraan pendapatan ACELYRIN, Inc. SLRN|Rega forward marang dodolan TFFP
